Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1992 Nov;90(5):1763–1768. doi: 10.1172/JCI116050

Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.

J Vincent 1, W Dachman 1, T F Blaschke 1, B B Hoffman 1
PMCID: PMC443234  PMID: 1358918

Abstract

Chronic administration of alpha 1-receptor antagonists is associated with loss of clinical efficacy, especially in congestive heart failure, although the mechanism is uncertain. To evaluate changes in venous alpha 1-adrenoceptor responsiveness during chronic alpha 1-adrenoceptor blockade, dose-response curves to phenylephrine and angiotensin II were constructed in 10 healthy subjects before, during, and after administration of terazosin 1 mg orally for 28 d. Terazosin initially shifted the dose-response curve of phenylephrine to the right, with a significant increase in ED50 for phenylephrine from a control value of 102 to 759 ng/min on day 1 of terazosin (P < 0.001). However, by day 28, the dose-response curve had shifted back towards baseline with an ED50 of 112 ng/min. After discontinuing terazosin, the ED50 for phenylephrine remained near the baseline value, indicating no evidence of supersensitivity to phenylephrine. There was no change in responsiveness to angiotensin II during the course of treatment with terazosin. Plasma terazosin concentrations were stable throughout the period of drug administration. The mean Kd of terazosin was estimated as 11 +/- 15 nM in the first few days of treatment. This study demonstrates that pharmacological tolerance to the alpha 1-adrenoceptor blocking action of terazosin occurs in man and may be responsible for loss in efficacy with chronic therapy.

Full text

PDF
1765

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarons R. D., Nies A. S., Gal J., Hegstrand L. R., Molinoff P. B. Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest. 1980 May;65(5):949–957. doi: 10.1172/JCI109781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aellig W. H. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol. 1981 Mar;11(3):237–243. doi: 10.1111/j.1365-2125.1981.tb00527.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arnold S. B., Williams R. L., Ports T. A., Baughman R. A., Benet L. Z., Parmley W. W., Chatterjee K. Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Intern Med. 1979 Sep;91(3):345–349. doi: 10.7326/0003-4819-91-3-345. [DOI] [PubMed] [Google Scholar]
  4. Awan N. A., Lee G., DeMaria A. N., Mason D. T. Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. Am Heart J. 1981 May;101(5):541–547. doi: 10.1016/0002-8703(81)90219-2. [DOI] [PubMed] [Google Scholar]
  5. Awan N. A., Mason D. T. Oral vasodilator therapy with prazosin in severe congestive heart failure. Am Heart J. 1981 May;101(5):695–700. doi: 10.1016/0002-8703(81)90250-7. [DOI] [PubMed] [Google Scholar]
  6. Beck A., Kraupp O., Bacher S., Seitelberger R., Raberger G. The influence of repeated administration of prazosin on its hypotensive effect and on renin release in conscious dogs. A comparison with urapidil. Basic Res Cardiol. 1984 Sep-Oct;79(5):579–587. doi: 10.1007/BF01910487. [DOI] [PubMed] [Google Scholar]
  7. Benovic J. L., Bouvier M., Caron M. G., Lefkowitz R. J. Regulation of adenylyl cyclase-coupled beta-adrenergic receptors. Annu Rev Cell Biol. 1988;4:405–428. doi: 10.1146/annurev.cb.04.110188.002201. [DOI] [PubMed] [Google Scholar]
  8. Bertel O., Burkart F., Bühler F. R. Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure. Am Heart J. 1981 May;101(5):529–533. doi: 10.1016/0002-8703(81)90217-9. [DOI] [PubMed] [Google Scholar]
  9. Bevan J. A., Oriowo M. A., Bevan R. D. Physiological variation in alpha-adrenoceptor-mediated arterial sensitivity: relation to agonist affinity. Science. 1986 Oct 10;234(4773):196–197. doi: 10.1126/science.3018932. [DOI] [PubMed] [Google Scholar]
  10. Caine M. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology. 1988 Dec;32(6 Suppl):16–20. [PubMed] [Google Scholar]
  11. Colucci W. S. Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications. Ann Intern Med. 1982 Jul;97(1):67–77. doi: 10.7326/0003-4819-97-1-67. [DOI] [PubMed] [Google Scholar]
  12. Colucci W. S., Gimbrone M. A., Jr, Alexander R. W. Regulation of the postsynaptic alpha-adrenergic receptor in rat mesenteric artery. Effects of chemical sympathectomy and epinephrine treatment. Circ Res. 1981 Jan;48(1):104–111. doi: 10.1161/01.res.48.1.104. [DOI] [PubMed] [Google Scholar]
  13. Colucci W. S., Williams G. H., Alexander R. W., Braunwald E. Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure. Am J Med. 1981 Jul;71(1):89–99. doi: 10.1016/0002-9343(81)90263-1. [DOI] [PubMed] [Google Scholar]
  14. Colucci W. S., Williams G. H., Braunwald E. Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. Ann Intern Med. 1980 Sep;93(3):452–453. doi: 10.7326/0003-4819-93-3-452. [DOI] [PubMed] [Google Scholar]
  15. Cramer J. A., Mattson R. H., Prevey M. L., Scheyer R. D., Ouellette V. L. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989 Jun 9;261(22):3273–3277. [PubMed] [Google Scholar]
  16. Cubeddu L. X. New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance. Am Heart J. 1988 Jul;116(1 Pt 1):133–162. doi: 10.1016/0002-8703(88)90261-x. [DOI] [PubMed] [Google Scholar]
  17. Davey M. J. Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension. Am J Med. 1989 Aug 16;87(2A):36S–44S. doi: 10.1016/0002-9343(89)90112-5. [DOI] [PubMed] [Google Scholar]
  18. Davey M. Mechanism of alpha blockade for blood pressure control. Am J Cardiol. 1987 May 29;59(14):18G–28G. doi: 10.1016/0002-9149(87)90153-6. [DOI] [PubMed] [Google Scholar]
  19. DeLean A., Munson P. J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978 Aug;235(2):E97–102. doi: 10.1152/ajpendo.1978.235.2.E97. [DOI] [PubMed] [Google Scholar]
  20. Desch C. E., Magorien R. D., Triffon D. W., Blanford M. F., Unverferth D. V., Leier C. V. Development of pharmacodynamic tolerance to prozosin in congestive heart failure. Am J Cardiol. 1979 Nov;44(6):1178–1182. doi: 10.1016/0002-9149(79)90185-1. [DOI] [PubMed] [Google Scholar]
  21. Dunzendorfer U. Clinical experience: symptomatic management of BPH with terazosin. Urology. 1988 Dec;32(6 Suppl):27–31. [PubMed] [Google Scholar]
  22. Eichler H. G., Ford G. A., Blaschke T. F., Swislocki A., Hoffman B. B. Responsiveness of superficial hand veins to phenylephrine in essential hypertension. Alpha adrenergic blockade during prazosin therapy. J Clin Invest. 1989 Jan;83(1):108–112. doi: 10.1172/JCI113845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Eklund B., Hjemdahl P., Seideman P., Atterhög J. H. Effects of prazosin on hemodynamics and sympatho-adrenal activity in hypertensive patients. J Cardiovasc Pharmacol. 1983 May-Jun;5(3):384–391. doi: 10.1097/00005344-198305000-00007. [DOI] [PubMed] [Google Scholar]
  24. Elkayam U., Lejemtel T. H., Mathur M., Ribner H. S., Frishman W. H., Strom J., Sonnenblick E. H. Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol. 1979 Sep;44(3):540–545. doi: 10.1016/0002-9149(79)90409-0. [DOI] [PubMed] [Google Scholar]
  25. Elliott H. L., Donnelly R., Meredith P. A., Reid J. L. Predictability of antihypertensive responsiveness and alpha-adrenoceptor antagonism during prazosin treatment. Clin Pharmacol Ther. 1989 Nov;46(5):576–583. doi: 10.1038/clpt.1989.188. [DOI] [PubMed] [Google Scholar]
  26. Feldman R. C., Ball R. M., Winchester M. A., Jaillon P., Kates R. E., Harrison D. C. Beneficial hemodynamic response to chronic prazosin therapy in congestive heart failure. Am Heart J. 1981 May;101(5):534–540. doi: 10.1016/0002-8703(81)90218-0. [DOI] [PubMed] [Google Scholar]
  27. Fleming W. W., Westfall D. P., De la Lande I. S., Jellett L. B. Log-normal distribution of equiefective doses of norepinephrine and acetylcholine in several tissues. J Pharmacol Exp Ther. 1972 May;181(2):339–345. [PubMed] [Google Scholar]
  28. Frishman W. H., Eisen G., Lapsker J. Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension. Med Clin North Am. 1988 Mar;72(2):441–448. doi: 10.1016/s0025-7125(16)30778-7. [DOI] [PubMed] [Google Scholar]
  29. Hamilton C. A., Reid J. L. Changes in alpha-adrenoceptors during long-term treatment of rabbits with prazosin. J Cardiovasc Pharmacol. 1981 Sep-Oct;3(5):977–985. doi: 10.1097/00005344-198109000-00007. [DOI] [PubMed] [Google Scholar]
  30. Izzo J. L., Jr, Horwitz D., Keiser H. R. Physiologic mechanisms opposing the hemodynamic effects of prazosin. Clin Pharmacol Ther. 1981 Jan;29(1):7–11. doi: 10.1038/clpt.1981.2. [DOI] [PubMed] [Google Scholar]
  31. Kyncl J. J. Pharmacology of terazosin. Am J Med. 1986 May 23;80(5B):12–19. doi: 10.1016/0002-9343(86)90846-6. [DOI] [PubMed] [Google Scholar]
  32. Leeb-Lundberg L. M., Cotecchia S., DeBlasi A., Caron M. G., Lefkowitz R. J. Regulation of adrenergic receptor function by phosphorylation. I. Agonist-promoted desensitization and phosphorylation of alpha 1-adrenergic receptors coupled to inositol phospholipid metabolism in DDT1 MF-2 smooth muscle cells. J Biol Chem. 1987 Mar 5;262(7):3098–3105. [PubMed] [Google Scholar]
  33. Lepor H., Gup D. I., Baumann M., Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology. 1988 Dec;32(6 Suppl):21–26. [PubMed] [Google Scholar]
  34. Lund-Johansen P. Effects of antihypertensive therapy on the hemodynamics of hypertension: clinical implications. Clin Ther. 1986;8(4):382–397. [PubMed] [Google Scholar]
  35. Luther R. R. New perspectives on selective alpha 1 blockade. Am J Hypertens. 1989 Sep;2(9):729–735. doi: 10.1093/ajh/2.9.729. [DOI] [PubMed] [Google Scholar]
  36. McAreavey D., Cumming A. M., Sood V. P., Leckie B. J., Morton J. J., Murray G. D., Robertson J. I. The effect of oral prazosin on blood pressure and plasma concentrations of renin and angiotensin II in man. Clin Sci (Lond) 1981 Dec;61 (Suppl 7):457s–460s. doi: 10.1042/cs061457s. [DOI] [PubMed] [Google Scholar]
  37. Packer M., Medina N., Yushak M. Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. J Am Coll Cardiol. 1986 Mar;7(3):671–680. doi: 10.1016/s0735-1097(86)80479-x. [DOI] [PubMed] [Google Scholar]
  38. Pan H. Y., Hoffman B. B., Pershe R. A., Blaschke T. F. Decline in beta adrenergic receptor-mediated vascular relaxation with aging in man. J Pharmacol Exp Ther. 1986 Dec;239(3):802–807. [PubMed] [Google Scholar]
  39. Patterson S. E. Rapid and sensitive analysis of terazosin in plasma, peritoneal dialysis solution, and urine using high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1984 Nov 9;311(1):206–212. doi: 10.1016/s0378-4347(00)84711-8. [DOI] [PubMed] [Google Scholar]
  40. Patterson S. E. Terazosin kinetics after oral and intravenous doses. Clin Pharmacol Ther. 1985 Oct;38(4):423–427. doi: 10.1038/clpt.1985.198. [DOI] [PubMed] [Google Scholar]
  41. Rangno R. E., Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol. Am Heart J. 1982 Aug;104(2 Pt 2):473–478. doi: 10.1016/0002-8703(82)90142-9. [DOI] [PubMed] [Google Scholar]
  42. Riegger G. A., Haeske W., Kraus C., Kromer E. P., Kochsiek K. Contribution of the renin-angiotensin-aldosterone system to development of tolerance and fluid retention in chronic congestive heart failure during prazosin treatment. Am J Cardiol. 1987 Apr 1;59(8):906–910. doi: 10.1016/0002-9149(87)91117-9. [DOI] [PubMed] [Google Scholar]
  43. Rubin P. C., Blaschke T. F. Studies on the clinical pharmacology of prazosin. I: Cardiovascular, catecholamine and endocrine changes following a single dose. Br J Clin Pharmacol. 1980 Jul;10(1):23–32. doi: 10.1111/j.1365-2125.1980.tb00498.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Shepherd A. M., Kwan C. M., Brodie C. L., Jamieson M. J. Determination of alpha-adrenergic blocking potency. Clin Pharmacol Ther. 1991 Jan;49(1):69–77. doi: 10.1038/clpt.1991.12. [DOI] [PubMed] [Google Scholar]
  45. Smith R. D., Tessman D. K., Kaplan H. R. Acute tolerance to prazosin in conscious hypertensive rats: involvement of the renin-angiotensin system. J Pharmacol Exp Ther. 1981 May;217(2):397–405. [PubMed] [Google Scholar]
  46. Sonders R. C. Pharmacokinetics of terazosin. Am J Med. 1986 May 23;80(5B):20–24. doi: 10.1016/0002-9343(86)90847-8. [DOI] [PubMed] [Google Scholar]
  47. Stein L., Henry D. P., Weinberger M. H. Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. Am J Med. 1981 Apr;70(4):825–832. doi: 10.1016/0002-9343(81)90539-8. [DOI] [PubMed] [Google Scholar]
  48. Titmarsh S., Monk J. P. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs. 1987 May;33(5):461–477. doi: 10.2165/00003495-198733050-00003. [DOI] [PubMed] [Google Scholar]
  49. von Bahr C., Lindström B., Seideman P. Alpha-receptor function changes after the first dose of prazosin. Clin Pharmacol Ther. 1982 Jul;32(1):41–47. doi: 10.1038/clpt.1982.124. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES